Two companies producing market-leading head lice products have released recent trading updates.
Pediapharm Inc have announced their second quarter financial results. They report that their head lice treatment NYDA is on track to reach over $2M in revenue in the fiscal year 2014-15. NYDA has an approximate market share of 10% and the company expects further revenue growth over coming years.
Tyratech Inc., in a recent trading update, have announced that their Vamousse head lice treatment is estimated as the second best-selling brand in Walmart following the expansion of their US retail network earlier this year.
The company expects to generate revenue from sales of $2.8M in fiscal year 2014-15. This is lower than market expectations due to a delay in the launch of Vamousse in several US retailers until the start of 2015.